The Alzheimer disease-related calcium-binding protein Calmyrin is present in human forebrain with an altered distribution in Alzheimer's as compared to normal ageing brains

Neuropathology and Applied Neurobiology

Volumn 31, Issue 3, 2005, Pages 314-324

  Bernstein, H G ^a   Blazejczyk, M ^b   Rudka, T ^b   Gundelfinger, E D ^c   Dobrowolny, H ^a   Bogerts, B ^a   Kreutz, M R ^c   Kuznicki, J ^d   Wojda, Urszula ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Alzheimer disease; Calmyrin; EF hand calcium binding proteins; Human brain; Immunohistochemistry; Interneurones; Presenilin 2; Pyramidal cells; Senile plaques

Indexed keywords

CALCIUM BINDING PROTEIN; CALMYRIN; PRESENILIN 2; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARCUATE NUCLEUS; ARTICLE; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOREBRAIN; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERNEURON; MALE; NEOCORTEX; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PYRAMIDAL NERVE CELL; SENILE PLAQUE; SEPTUM NUCLEUS; SIGNAL TRANSDUCTION; THALAMUS MIDLINE NUCLEUS; THALAMUS NUCLEUS; THALAMUS VENTRAL NUCLEUS;

ADULT; AGED; AGING; ALZHEIMER DISEASE; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEURONS; PROSENCEPHALON; SENILE PLAQUES;

EID: 20044386942     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2005.00646.x     Document Type: Article

References (31)

1. Cummings JL. Toward a molecular neuropsychiatry of neurodegenerative diseases. Ann Neurol 2003; 54 (2): 147-54
2. Sorbi S, Forleo P, Tedde A, Cellini E, Ciantelli M, Bagnoli S, Nacmias B. Genetic risk factors in familial Alzheimer's disease. Mech Ageing Dev 2001; 122 (16): 1951-60
3. St George-Hyslop PH. Molecular genetics of Alzheimer's disease. Biol Psychiatry 2000; 47 (3): 183-99
4. Sastre M, Steiner H, Fuchs K, Capell A, Multhaup G, Condron MM, Teplow DB, Haass C. Presenilin-dependent gamma-secretase processing of beta-amyloid precursor protein at a site corresponding to the S3 cleavage of Notch. EMBO Rep 2001; 2 (9): 835-41
5. Choi EK, Zaidi NF, Miller JS, Crowley AC, Merriam DE, Lilliehook C, Buxbaum J, Wasco W. Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer's disease-associated C-terminal fragment of presenilin 2. J Biol Chem 2001; 276 (22): 19197-204
6. Czech C, Tremp G, Pradier L. Presenilins and Alzheimer's disease: biological functions and pathogenic mechanisms. Prog Neurobiol 2000; 60 (4): 363-84
7. Buxbaum JD, Choi EK, Luo Y, Lilliehook C, Crowley AC, Merriam DE, Wasco W. Calsenilin: a calcium-binding protein that interacts with the presenilins and regulates the levels of a presenilin fragment. Nat Med 1998; 4 (10): 1177-81
8. Pack-Chung E, Meyers MB, Pettingell WP, Moir RD, Brownawell AM, Cheng I, Tanzi RE, Kim TW. Presenilin 2 interacts with sorcin, a modulator of the ryanodine receptor. J Biol Chem 2000; 275 (19): 14440-5
9. Stabler SM, Ostrowski LL, Janicki SM, Monteiro MJ. A myristoylated calcium-binding protein that preferentially interacts with the Alzheimer's Disease presenilin 2 protein. J Cell Biol 1999; 145 (6): 1277-92
10. Huynh DP, Vinters HV, Ho DH, Ho VV, Pulst SM. Neuronal expression and intracellular localization of presenilins in normal and Alzheimer disease brains. J Neuropathol Exp Neurol 1997; 56 (9): 1009-117
11. McGeer PL, Kawamata T, McGeer EG. Localization and possible functions of presenilins in brain. Rev Neurosci 1998; 9 (1): 1-15
12. Bernstein H-G, Seidenbecher CI, Smalla K-H, Gundelfinger ED, Bogerts B, Kreutz MR. Distribution and cellular localization of caldendrin immunoreactivity in adult human forebrain. J Histochem Cytochem 2003; 51: 1109-12
13. Bernstein H-G, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B. Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 1998; 83: 867-75
14. Mirra SS, Heymann A, McKeel D, Sumi S, Crain BJ, Brownbee LM, Vogel FS, Hughes U, Belle G, Bergh L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathological assessment of Alzheimer's disease. Neurology 1991; 41: 479-86
15. Bernstein H-G, Ansorge S, Riederer P, Reiser M, Fröhlich L, Bogerts B. Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 1999; 263: 161-4
16. Bernstein H-G, Baumann B, Danos P, Diekmann S, Bogerts B, Gundelfinger ED, Braunewell K-H. Regional and cellular distribution of visin-like immunoreactivities (VILIP-1 and VILIP-3) in human brain. J Neurocytol 1999; 28: 655-62
17. Harding AJ, Kril JJ, Halliday G. Practical measures to simplify the Braak stain method for routine pathological screening. J Mol Neuroscience 2000; 99: 199-208
18. Bernstein H-G, Bukowska A, Krell D, Bogerts B, Ansorge S, Lendeckel U. Comparative localization of ADAMs 10 and 15 in human cerebral cortex: normal aging, Alzheimer disease and Down syndrome. J Neurocytol 2003; 32: 153-60
19. 2+-binding protein caldendrin: gene structure, splice isoforms, and expression in the rat central nervous system. Mol Cell Neurosci 2002; 19: 459-75
20. Braunewell KH, Gundelfinger ED. Intracellular neuronal calcium sensor proteins: a family of EF-hand calcium-binding proteins in search of a function. Cell Tissue Res 1999; 295: 1-12
21. 2+-binding proteins. Biochem J 2001; 353: 1-12
22. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297 (5580): 353-6
23. Hölscher C. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 1998; 5 (3): 129-41
24. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER. its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000; 23 (5): 222-9
25. Mattson MP, Chan SL. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J Mol Neurosci 2001; 17: 205-24
26. Paschen W. Dependence of vital cell function on endoplasmic reticulum calcium levels: implications for the mechanisms underlying neuronal cell injury in different pathological states. Cell Calcium 2001; 29: 1-11
27. Querfurth HW, Selkoe DJ. Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 1994; 33 (15): 4550-61
28. Naik UP, Patel PM. Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphallb cytoplasmic domain. J Biol Chem 1997; 272 (8): 4651-4
29. Ma S, Liu MA, Yuan YL, Erikson RL. The serum-inducible protein kinase Snk is a G1 phase polo-like kinase that is inhibited by the calcium- and integrin-binding protein CIB. Mol Cancer Res 2003; 1 (5): 376-84
30. 2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J 1999; 18 (20): 5528-39
31. Harris PI, Zhu X, Pamies C, Rottkamp CA, Ghanbari HA, McShea A, Feng Y. Ferris DK, Smith MA. Neuronal polo-like kinase in Alzheimer disease indicates cell cycle changes. Neurobiol Aging 2000; 21: 837-41